Evidence-Based Diagnosis & Management of Multiple Sclerosis
Neurology
Curriculum:
Evidence-Based Diagnosis & Management of Multiple Sclerosis
Evidence-Based Diagnosis & Management of Multiple Sclerosis
Credits:
AANP Contact Hours 0.5 ANCC Contact Hours 0.5 AMA PRA Category 1 Credit(s) ™
AANP Contact Hours 0.5 ANCC Contact Hours 0.5 AMA PRA Category 1 Credit(s) ™
Launch Date:
June 28, 2018
June 28, 2018
Expiration Date:
The accreditation for this activity has expired.
The accreditation for this activity has expired.
Primary Audience:
Neurology clinicians, including physicians, nurse practitioners, physician assistants, and neurology nurses
Relevant Terms:
Multiple Sclerosis, MS, Autoimmune Neurological Disorders
Patricia K. Coyle, MD, FAAN, FANA
Patricia K. Coyle, MD, FAAN, FANA
Professor & Vice Chair (Clinical Affairs)
Department of Neurology
Director, MS Comprehensive Care Center
Stony Brook University Medical Center
Stony Brook, NY
Bio
Professor & Vice Chair (Clinical Affairs)
Department of Neurology
Director, MS Comprehensive Care Center
Stony Brook University Medical Center
Stony Brook, NY
Patricia K. Coyle, MD, FAAN, FANA, is a professor and the vice chair (Clinical Affairs) of neurology, and director of the Multiple Sclerosis Comprehensive Care Center at Stony Brook University Medical Center, Stony Brook, NY. She received her bachelor of science degree, with highest honors, from Fordham University, Bronx, NY, and her medical degree from the Johns Hopkins School of Medicine, where she was elected to Alpha Omega Alpha. While at the Johns Hopkins School of Medicine, she completed a residency and chief residency in neurology, followed by a 2-year fellowship in neuroimmunology and neurovirology. She then went on to establish a successful research laboratory in addition to building a busy clinical practice at the Stony Brook University Medical Center.
Dr Coyle is the author of numerous articles on clinical and basic research aspects of multiple sclerosis (MS) and neurologic infections and she is recognized as a leading expert on MS and neurologic infections. Her areas of expertise include Lyme disease and neurologic infections, cerebrospinal fluid, therapeutics, and neuroimmunology. Her research has been supported by the National Institutes of Health and other organizations. Dr Coyle is currently involved in a number of therapeutic trials testing new immunotherapies for MS, as well as studies addressing neurologic aspects of Lyme disease.
In addition to her busy clinical and research careers, Dr Coyle has held active leadership positions in a number of national and international organizations and academic societies, including the American Academy of Neurology, American Neurological Association, National MS Society, and the American Board of Psychiatry and Neurology, and has been a member of the FDA CNS and PNS Drugs Advisory Panel. She lectures widely on MS and neurologic infections to national and international audiences.
| 1. | Recognize and diagnose the spectrum of multiple sclerosis (MS), from clinically isolated syndrome (CIS) to the various forms of MS (relapsing-remitting and progressive forms), using established, updated clinical, imaging, and laboratory criteria | 2. | Appropriately use available and emerging disease-modifying therapies (DMTs) for MS based on their efficacy, safety, and tolerability profiles, as well as their approved or anticipated indications for the various forms of MS |
| 3. | Recognize and manage treatment failure, including switching DMTs | 4. | Monitor disease and patient outcomes, including patient adherence, according to recommended protocols |
| 5. | Use shared decision making when prescribing DMTs to improve treatment adherence and patient outcomes |
| 1. | Recognize and diagnose the spectrum of multiple sclerosis (MS), from clinically isolated syndrome (CIS) to the various forms of MS (relapsing-remitting and progressive forms), using established, updated clinical, imaging, and laboratory criteria |
| 2. | Appropriately use available and emerging disease-modifying therapies (DMTs) for MS based on their efficacy, safety, and tolerability profiles, as well as their approved or anticipated indications for the various forms of MS |
| 3. | Recognize and manage treatment failure, including switching DMTs |
| 4. | Monitor disease and patient outcomes, including patient adherence, according to recommended protocols |
| 5. | Use shared decision making when prescribing DMTs to improve treatment adherence and patient outcomes |
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and RMEI Medical Education, LLC. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 0.5 contact hour(s). Designated for 0.5 contact hours of pharmacotherapy credit for Advanced Practice Registered Nurses.
DISCLOSURE OF CONFLICTS OF INTEREST
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
Patricia K. Coyle, MD, FAAN, FANA, has affiliations with Accordant, Acorda Therapeutics, Bayer, Biogen, Celgene, Genentech/Roche, Genzyme/Sanofi, Novartis, and Serono (Consulting); Actelion, Genentech/Roche, MedDay, NINDS, and Novartis (Contracted Research).
Planners and Managers
The PIM planners and managers have nothing to disclose. RMEI Medical Education, LLC planners and managers have nothing to disclose.
DISCLAIMER
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Estimated time to complete: 30 minutes
Media: Internet
FEE INFORMATION
There is no fee for this educational activity.
STATEMENT OF SUPPORT
Jointly provided by RMEI Medical Education, LLC and Postgraduate Institute for Medicine. This activity is supported by an educational grant from Biogen, Genentech, and Novartis Pharmaceuticals Corporation.
HOW TO RECEIVE CREDIT
By reviewing the course content and successfully completing the post-test and evaluation, physicians, nurse practitioners, registered nurses, and PAs are entitled to receive up to 0.5 AMA PRA Category 1 Credit(s)™, 0.5 ANCC contact hour, and 0.5 APRN contact hour. A statement of credit will be available to print from your user history page. Users must:
- Read the learning objectives and faculty disclosures.
- Participate in the activity.
- Complete the activity evaluation.
Physicians, nurse practitioners, registered nurses, and PAs who successfully complete the post-test and evaluation will receive CME credit. You must score 75% or higher on the post-test to receive credit for this activity. All other participants who successfully complete the post-test and evaluation will receive a certificate of participation. If you would like to contact Postgraduate Institute for Medicine, please email information@pimed.com.
COURSE VIEWING REQUIREMENTS
| Supported Browsers: Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above Google Chrome 28.0+ for Windows, Mac OS, or Linux Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux Safari 6.0+ for Mac OSX 10.7 and above | Supported Phones & Tablets: Android 4.0.3 and above iPhone/iPad with iOS 6.1 or above. |
© 2007-2024 HealthCourse, Inc. All rights reserved.
